Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...

Dementia is a condition that affects memory, thinking, and the ability to perform everyday tasks. As it progresses, it can ...

Raquel Sánchez Valle, coordinator of the Behavior and Dementia Group of the Spanish Society ... Given the complexity of ...

Alzheimer’s disease robs patients of so much more than their health. It can rewire their personalities and undermine a ...

The global neuromodulation device market will be worth $11.4bn by 2033, as per a market model from GlobalData.

Researchers at Case Western Reserve school of Medicine looked at nearly one million patients in the U.S. with Type 2 diabetes ...

Can large national health plans make an impact in reducing prescribing of high-risk medications to people with Alzheimer's ...

For years, scientists have observed a connection between type 2 diabetes and an increased risk of dementia, particularly ...

Cannabis is emerging as a tool in dementia care, offering relief from anxiety and agitation when traditional medications fall ...

As people age, the body changes as part of the normal ageing process, such as greying hair and loss of elasticity in the skin ...

We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...

A compassionate, multidisciplinary approach can help manage one of the most complex challenges nursing homes and other long-term care providers face.